Flecainide is most effective in premature ventricular contractions suppression at plasma concentrations in the range of 0.2 to 1.0 mcg/mL.
Plasma concentrations >1.0 mcg/mL are associated with a high rate of cardiac adverse experiences such as conduction defects or bradycardia.
Therapeutic concentration (Trough Value): 0.2 to 1.0 mcg/mL
Toxic concentration (Trough Value): >1.0 mcg/mL